Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NCT02834013Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in rare cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 10 years. Started Jan 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
rare cancer
Beyond the preview
Go deeper on NCT02834013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834013.